Renal dysfunctions/injury in adult epilepsy patients treated with carbamazepine or valproate

References

• Hauser WA. Incidence and prevalence. In: Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997. p. 47–57.
   Google Scholar
• Kandil MR, Ahmed WA, Sayed AM, et al. Pattern of epilepsy in childhood and adolescence: a hospital-based study. African J Neurol Scien. 2007;26(1):33–45.
   Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–319.
   PubMed Web of Science ®Google Scholar
• Hamed SA, Fida NM, Hamed EA. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. European J Ped Neurol. 2009;13(3):261–268.
   PubMed Web of Science ®Google Scholar
• Hamed SA. Antiepileptic drugs (AEDs) influences on weight in people with epilepsy. Expert Rev Clin Pharmacol. 2015;8(1):103–114.
   PubMed Web of Science ®Google Scholar
• Hamed SA, Hamed EA, Hamdy R, et al. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res. 2007;74(2–3):183–192.
   PubMed Web of Science ®Google Scholar
• Hamed SA. The aspects and mechanisms of cognitive alterations in epilepsy: the role of antiepileptic medications. CNS Neurosci Ther. 2009;15(2):134–156.
   PubMed Web of Science ®Google Scholar
• Hamed SA, Elserogy YE, Abdou MA, et al. The risks of suicidality in adult patients with epilepsy. World J Psych. 2012;2(2):33–42.
   PubMedGoogle Scholar
• Luef G, Rauchenzauner M, Waldmann M, et al. Non-alcoholic fatty liver disease (FLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009;86(1):42–47.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Di Marco G, la Torre R, et al. Nonalcoholic fatty liver disease during valproate therapy. Eur J Pediatr. 2009;168(11):1391–1394.
   PubMed Web of Science ®Google Scholar
• Hamed SA, Radwan MEM, Abd-Elaal RF, et al. Fatty liver in adults with epilepsy receiving antiepileptic medications: relationship to the associated metabolic risks. Exp Rev Clin Pharmacol. 2016;9(4):617–624.
   Web of Science ®Google Scholar
• Lin CY, Chiang H. Sodium-valproate-induced interstitial nephritis. Nephron. 1988;48(1):43–46.
   PubMed Web of Science ®Google Scholar
• Lambert M, Fournier A. Acute renal failure complicating carbamazepine hypersensitivity. Rev Neurol (Paris). 1992;148(8–9):574–576.
   PubMed Web of Science ®Google Scholar
• Eguchi E, Shimazu K, Nishiguchi K, et al. Granulomatous interstitial nephritis associated with atypical drug-induced hypersensitivity syndrome induced by carbamazepine. Clin Exp Nephrol. 2012;16(1):168–172.
   PubMed Web of Science ®Google Scholar
• Mirza NS, Alfirevic A, Jorgensen A, et al. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genom. 2011;21(5):297–302.
   PubMed Web of Science ®Google Scholar
• Fukumoto R, Katayama K, Hayashi T, et al. [Two cases of urolithiasis induced by topiramate]. Hinyokika Kiyo. 2011;57(3):125–128.
   PubMedGoogle Scholar
• Shen AL, Lin HL, Tseng YF, et al. Topiramate may not increase risk of urolithiasis: a nationwide population-based cohort study. Seizure. 2015;29:86–89.
   PubMed Web of Science ®Google Scholar
• Inoue T, Kira R, Kaku Y, et al. Renal tubular acidosis associated with zonisamide therapy. Epilepsia. 2000;41(12):1642–1644.
   PubMed Web of Science ®Google Scholar
• Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007;23(8):1765–1773.
   PubMed Web of Science ®Google Scholar
• Matsuda I, Takekoshi Y, Shida N, et al. Renal tubular acidosis and skeletal demineralization in patients on long-term anticonvulsant therapy. J Pediatr. 1975;87(2):202–205.
   PubMed Web of Science ®Google Scholar
• Jr RSR, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology. 1990;40(11):1677–1681.
   PubMed Web of Science ®Google Scholar
• Zaki EL, Springate JE. Renal injury from valproic acid: case report and literature review. Pediatr Neurol. 2002;27(4):318–319.
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Watanabe T, Abe T. Fanconi syndrome caused by sodium valproate: report of three severely disabled children. Eur J Paediatr Neurol. 2002;6(3):165–167.
   PubMedGoogle Scholar
• Knorr M, Schaper J, Harjes M, et al. Fanconi syndrome caused by antiepileptic therapy with valproic Acid. Epilepsia. 2004;45(7):868–871.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Yoshikawa H, Yamazaki S, et al. Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol. 2005;20(6):814–817.
   PubMed Web of Science ®Google Scholar
• Dhillon N, Fractures HW. Fanconi syndrome due to prolonged sodium valproate use. Neuropediatrics. 2011;42(3):119–121.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Watanabe T, Sato S, et al. Outcome of renal proximal tubular dysfunction with Fanconi syndrome caused by sodium valproate. Pediatr Int. 2016;58(10):1023–1026.
   PubMed Web of Science ®Google Scholar
• Knights M, Thekkekkara T, Morris A, et al. Sodium valproate-induced Fanconi type proximal renal tubular acidosis. BMJ Case Rep. 2016;2016.
   Google Scholar
• Tseng CL, Wang PJ, Tsau YK, et al. Urinary N-acetyl-beta-glucosaminidase (NAG) in children receiving antiepileptic drugs. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1992;33(4):251–256.
   Google Scholar
• de Novo ML, Izumi T, Yokota K, et al. Urinary excretion of N-acetyl-beta-glucosaminidase and beta-galactosidase by patients with epilepsy. Brain Dev. 1993;15(2):157–160.
   PubMed Web of Science ®Google Scholar
• Otsuka T, Sunaga Y, Urinary HA. N-acetyl-beta-glucosaminidase and guanidinoacetic acid levels in epileptic patients treated with anti-epileptic drugs. Brain Dev. 1994;16(6):437–440.
   PubMed Web of Science ®Google Scholar
• Yüksel A, Cengiz M, Seven M, et al. N-acetyl-beta-glucosaminidase and beta-galactosidase activity in children receiving antiepileptic drugs. Pediatr Neurol. 1999;20(1):24–62.
   PubMed Web of Science ®Google Scholar
• Csáthy L, Oláh AV, Clemens B, et al. Urinary N-acetyl-beta-D-glucosaminidase in epileptic children treated with antiepileptic drugs. Arch Dis Child. 2000;83(5):420–422.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Greco R, Pascarella R, et al. Renal tubular function in patients receiving anticonvulsant therapy: a long-term study. Epilepsia. 2000;41(11):1432–1435.
   PubMed Web of Science ®Google Scholar
• Altunbaşak S, Yildizaş D, Anarat A, et al. Renal tubular dysfunction in epileptic children on valproic acid therapy. Pediatr Nephrol. 2001;16(3):256–259.
   PubMed Web of Science ®Google Scholar
• Hurkacz M., Wiela-Hojeńska A, Orzechowska-Juzwenko K, Kozik A, Unolt J. Monitoring of Renal Function in Epileptic Children and Teenagers Treated with Valproic Acid or Carbamazepine in Concomitant Therapy with Tiagabine. Pol Merkur Lekarski. 2001;11(66):480–483.
   PubMedGoogle Scholar
• Mazaheri M, Samaie A, Semnani V. Renal tubular dysfunction measured by N-acetyl-beta glucosaminidase/Creatinine activity index in children receiving antiepileptic drugs: a randomized controlled trial. Ital J Pediatr. 2011;37:21.
   PubMed Web of Science ®Google Scholar
• Unay B, Akin R, Sarici SU, et al. Evaluation of renal tubular function in children taking anti-epileptic treatment. Nephrology (Carlton). 2006;11(6):485–488.
   PubMed Web of Science ®Google Scholar
• Havali C, Gücüyener K, Buyan N, et al. Does nephrotoxicity exist in pediatric epileptic patients on valproate or carbamazepine therapy? J Child Neurol. 2015;30(3):301–306.
   PubMed Web of Science ®Google Scholar
• Raza M, Al-Bekairi AM, Ageel AM, et al. Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury. Pharmacol Res. 1997;35(2):153–157.
   PubMed Web of Science ®Google Scholar
• Chaudhary S, Ganjoo P, Raiusddin S, et al. Nephroprotective activities of quercetin with potential relevance to oxidative stress induced by valproic acid. Protoplasma. 2015;252(1):209–217.
   PubMed Web of Science ®Google Scholar
• Gezginci-Oktayoglu S, Turkyilmaz IB, Ercin M, et al. U has a protective effect on valproic acid-induced renal damage due to its anti-oxidant, anti-inflammatory, and anti-fibrotic properties. Protoplasma. 2016;253(1):127–135.
   PubMed Web of Science ®Google Scholar
• Soni SS, Ronco C, Katz N, et al. Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purif. 2009;28(3):165–174.
   PubMed Web of Science ®Google Scholar
• Urbschat A, Obermüller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers. 2011;16(Suppl 1):S22–30.
   PubMed Web of Science ®Google Scholar
• van Timmeren MM, Bakker SJ, Vaidya VS, et al. Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol. 2006;291(2):F456–464.
   PubMed Web of Science ®Google Scholar
• Bailly V, Zhang Z, Meier W, et al. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem. 2002;277(42):39739–39748.
   PubMed Web of Science ®Google Scholar
• Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512–521.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Keane WF. Laboratory assessment of renal disease: clearance, urinalysis and renal biopsy. In: BM Brenner, ed. The Kidney. 6th ed. Philadelphia, PA: WB Saunders Company; 2000. 1129–1170.
   Google Scholar
• Hergüner MO, Altunbaşak S, Doğan A, et al. Effects of sodium valproate on renal functions in rats. Ren Fail. 2006;28(7):593–597.
   PubMed Web of Science ®Google Scholar
• van Beneden K, Geers C, Pauwels M, et al. Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol. 2011;22(10):1863–1875.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis.2002;39(2 Suppl 1):S1–266.
   PubMed Web of Science ®Google Scholar
• Hamed SA. The effect of antiepileptic drugs on the kidney structure and function. Expert Rev Clin Pharmacol. 2017;10(9):993–1006.
   PubMed Web of Science ®Google Scholar